ArticleClinical case reports2026
A Hidden Culprit: Aldosteronoma as a Rare Cause of Refractory Hypertension in Autosomal-Dominant Polycystic Kidney Disease.
Article in Clinical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertension is common in autosomal-dominant polycystic kidney disease (ADPKD) but may occasionally reflect a secondary etiology. We report a 71-year-old man with ADPKD and end-stage renal disease who developed persistent, refractory hypertension following renal transplantation despite multidrug therapy and bilateral native nephrectomy. Evaluation revealed an elevated aldosterone-to-renin ratio, and adrenal venous sampling confirmed unilateral aldosterone excess consistent with a left aldosterone-producing adenoma. The patient underwent robotic adrenalectomy with subsequent improvement in blood pressure control and reduced antihypertensive requirements. This case highlights the importance of evaluating for primary hyperaldosteronism in patients with ADPKD and resistant hypertension, even in the setting of advanced renal disease or prior nephrectomy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.